Skip to main content
Thursday, November 12, 2026Nov 12

The Latest: Price transfers business ownership to wife

FILE - In this Tuesday, Jan. 10, 2017, file photo, Attorney General-designate, Sen. Jeff Sessions, R-Ala. testifies on Capitol Hill in Washington at his confirmation hearing before the Senate Judiciary Committee. The Senate is working overtime toward confirming President Donald Trump's close ally, Sessions, to become the nation's top law enforcement officer as attorney general. (AP Photo/Andrew Harnik, File)
FILE - In this Tuesday, Jan. 10, 2017, file photo, Attorney General-designate, Sen. Jeff Sessions, R-Ala. testifies on Capitol Hill in Washington at his confirmation hearing before the Senate Judiciary Committee. The Senate is working overtime toward confirming President Donald Trump's close ally, Sessions, to become the nation's top law enforcement officer as attorney general. (AP Photo/Andrew Harnik, File) FILE - In this Tuesday, Jan. 10, 2017, file photo, Attorney General-designate, Sen. Jeff Sessions, R-Ala. testifies on Capitol Hill in Washington at his confirmation hearing before the Senate Judiciary Committee. The Senate is working overtime toward confirming President Donald Trump's close ally, Sessions, to become the nation's top law enforcement officer as attorney general. (AP Photo/Andrew Harnik, File)

WASHINGTON (AP) – The Latest on President Donald Trump’s Cabinet nominations (all times local):

11:40 a.m.

Tom Price, President Donald Trump’s pick for health secretary, has amended his government ethics agreement as the Senate prepares to debate and vote on his confirmation.

In the amended agreement released Wednesday, Price says he has transferred ownership interest in a business to his wife. A Senate aide says the company – Chattahoochee Associates LP – is involved with medical buildings. Price had previously said he would resign as managing partner but maintain a financial interest.

Price also reaffirmed that he will sell his stock in Innate Immunotherapeutics, an Australian company trying to develop a drug for multiple sclerosis. Democrats have criticized his purchase of the company’s stock at a discount. In the new agreement, Price corrected a previous reporting error that undervalued his stake.